Search JIM
Advanced Search
Journal of Chinese Integrative Medicine ›› 2013, Vol. 11 ›› Issue (3): 184-194.doi: 10.3736/jintegrmed2013031
• Research Article • Previous Articles Next Articles
Yi Chena, De-yu Fub, Yu Chenb,c, Yan-ming Heb, Xiao-dong Fua, Yan-qiu Xub, Yi Liua, Xiao-tao Fenga, Teng Zhangb,c(
), Wen-jian Wanga,c()
| [1] |
Scholze J, Alegria E, Ferri C, Langham S, Stevens W, Jeffries D, Uhl-Hochgraeber K . Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in Germany, Spain and Italy; a prevalence-based model[J]. BMC Public Health, 2010,10:529
doi: 10.1186/1471-2458-10-529 |
| [2] |
Andreadis EA, Tsourous GI, Tzavara CK, Georgiopoulos DX, Katsanou PM, Marakomichelakis GE, Diamantopoulos EJ . Metabolic syndrome and incident cardiovascular morbidity and mortality in a Mediterranean hypertensive population[J]. Am J Hypertens, 2007,20(5):558-564
doi: 10.1016/j.amjhyper.2006.12.001 |
| [3] |
Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C, Mannarino E . Prognostic value of the metabolic syndrome in essential hypertension[J]. J Am Coll Cardiol, 2004,43(10):1817-1822
doi: 10.1016/j.jacc.2003.12.049 |
| [4] |
Obesity in Asia Collaboration . Is central obesity a better discriminator of the risk of hypertension than body mass index in ethnically diverse populations?[J] Hypertens. 2008; 26(2):169-177.
doi: 10.1097/HJH.0b013e3282f16ad3 |
| [5] |
He CY, Wang WJ, Li B, Xu DS, Chen WH, Ying J, He YM . Clinical research of Yiqi Sanju Formula in treating central obese men at high risk of metabolic syndrome[J]. J Chin Integr Med, 2007,5(3):263-267
doi: 10.3736/jcim |
| [6] |
Lou SY, Liu Y, Ma YY, Chen HY, Chen WH, Ying J, He YM, Wang WJ . Effects of Yiqi Sanju Formula on non-alcoholic fatty liver disease: a randomized controlled trial[J]. J Chin Integr Med, 2008,6(8):793-798
doi: 10.3736/jcim |
| [7] |
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial(ALLHAT)[J]. Hypertension, 2003,42(3):239-246
doi: 10.1161/01.HYP.0000086521.95630.5A |
| [8] | Joint Committee for Developing Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults. Chinese guidelines on prevention and treatment of dyslipidemia in adults[J]. Zhonghua Xin Xue Guan Bing Za Zhi, 2007,35(5):390-419 |
| [9] |
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure[J]. Hypertension, 2003,42(6):1206-1252
doi: 10.1161/01.HYP.0000107251.49515.c2 |
| [10] |
Bianchi C, Penno G, Daniele G, Benzi L, Del Prato S, Miccoli R . Optimizing management of metabolic syndrome to reduce risk: focus on life-style[J]. Intern Emerg Med, 2008,3(2):87-98
doi: 10.1007/s11739-008-0122-6 |
| [11] |
Zhang X, Sun Z, Zhang X, Zheng L, Li J, Liu S, Xu C, Li J, Zhao F, Hu D, Sun Y . Prevalence of metabolic syndrome in Han and Mongolian rural population with hypertension[J]. J Int Med Res, 2007,35(5):597-599
doi: 10.1177/147323000703500503 |
| [12] |
Cheung BM, Wat NM, Man YB, Tam S, Cheng CH, Leung GM, Woo J, Janus ED, Lau CP, Lam TH, Lam KS . Relationship between the metabolic syndrome and the development of hypertension in the Hong Kong Cardiovascular Risk Factor Prevalence Study-2(CRISPS2)[J]. Am J Hypertens, 2008,21(1):17-22
doi: 10.1038/ajh.2007.19 |
| [13] |
Ho JS, Cannaday JJ, Barlow CE, Mitchell TL, Cooper KH , FitzGerald SJ.Relation of the number of metabolic syndrome risk factors with all-cause and cardiovascular mortality[J]. Am J Cardiol, 2008,102(6):689-692
doi: 10.1016/j.amjcard.2008.05.010 |
| [14] |
Ong KL, Cheung BM, Man YB, Lau CP, Lam KS . Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004[J]. Hypertension, 2007,49(1):69-75
doi: 10.1161/01.HYP.0000252676.46043.18 |
| [15] | Li W, Lu WL, Wang Y, Li YL, Sun YM, Huang GW, Wang Z, Wang JH . Association between blood pressure control and risk factor in community hypertensive patients[J]. Zhongguo Gong Gong Wei Sheng, 2012,28(2):154-156 |
| [16] | Wang WJ, Liu Y . Differentiation on “spleen-deficiency resulting in obstacle of transport” and “spleen-deficiency resulting in obstacle of transformation”[J]. Shanghai Zhong Yi Yao Da Xue Xue Bao, 2013,27(1):8-10 |
| [17] | Liu Y, Wang WJ, Chen WH, Yin J . Effects of Astragalus polysaccharides on proliferation and differentiation of 3T3-L1 preadipocytes[J]. J Chin Integr Med, 2007,5(4):421-426 |
| [18] |
He YM, Wang WJ, Chen WH, Ying J . Effects of Pollen Typhae total flavones on mRNA expressions of peroxisome proliferator-activated receptors in 3T3-L1 adipocytes[J]. J Chin Integr Med, 2008,6(9):939-941
doi: 10.3736/jcim |
| [19] | Liu Y, Lou SY, He YM . Effects of berberine on cell proliferation, peroxisome proliferation activated receptor gamma, CAAT/enhancer binding protein mRNA and protein expression in 3T3-L1 pre-adipocytes[J]. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2008,28(11):1005-1009 |
| [20] |
Rothwell PM, Howard SC, Dolan E , O’Brien E, Dobson JE, Dahl?f B, Sever PS, Poulter NR.Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension[J]. Lancet, 2010,375(9718):895-905
doi: 10.1016/S0140-6736(10)60308-X |
| [21] |
Tatasciore A, Renda G, Zimarino M, Soccio M, Bilo G, Parati G, Schillaci G, De Caterina R . Awake systolic blood pressure variability correlates with target-organ damage in hypertensive subjects[J]. Hypertension, 2007,50(2):325-332
doi: 10.1161/HYPERTENSIONAHA.107.090084 |
| [22] |
Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G . Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension[J]. J Hypertens, 1987,5(1):93-98
doi: 10.1097/00004872-198702000-00013 |
| [23] | Ievleva GI, Teslia EF, Biktimirova DM, Kiklevich AV, Erdakova TK . Parameters of 24-hour arterial pressure in patients with metabolic syndrome[J]. Klin Med (Mosk), 2009,87(6):15-18 |
| [24] |
Dahl?f B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J; ASCOT Investigators . Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm(ASCOT-BPLA): a multicentre randomised controlled trial[J]. Lancet, 2005,366(9489):895-906
doi: 10.1016/S0140-6736(05)67185-1 |
| [25] | Aalbers J . Reduced blood pressure variability in ASCOT-BPLA trial favours use of amlodipine/perindopril combination to reduce stroke risk[J]. Cardiovasc J Afr, 2010,21(2):115 |
| [26] |
Webb AJ, Fischer U, Mehta Z, Rothwell PM . Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis[J]. Lancet, 2010,375(9718):906-915
doi: 10.1016/S0140-6736(10)60235-8 |
| [27] | Clement DL, De Buyzere M, Duprez DD . Influence of drugs on blood pressure variability[J]. J Hypertens Suppl, 1994,12(8):S49-S53 |
| [28] |
Mancia G, Casadel R, Mutti E, Trazzi S, Parati G . Ambulatory blood pressure monitoring in the evaluation of antihypertensive treatment. Am[J] Med. 1989; 87(6B):64S-69S.
doi: 10.1016/S0002-9343(89)80933-7 |
| [29] | Mulè G, Nardi E, Andronico G, Cottone S, Raspanti F, Piazza G, Volpe V, Ferrara D, Cerasola G. Relationships between 24 h blood pressure load and target organ damage in patients with mild-to-moderate essential hypertension[J].Blood Press Monit, 2001,6(3):115-123 |
| [30] | Falqui V, Viazzi F, Leoncini G, Ratto E, Parodi A, Conti N, Tomolillo C, Deferrari G, Pontremoli R . Blood pressure load, vascular permeability and target organ damage in primary hypertension[J]. J Nephrol, 2007,20(Suppl 12):S63-S67 |
| [31] |
Mancia G, Di Rienzo M, Parati G . Ambulatory blood pressure monitoring use in hypertension research and clinical practice[J]. Hypertension, 1993,21(4):510-524
doi: 10.1161/01.HYP.21.4.510 |
| [32] |
Chen Y, Wang WJ . Relationships between insulin resistant and hypertension and traditional Chinese medicine intervention[J]. J Chin Integr Med, 2010,8(12):1114-1118
doi: 10.3736/jcim201012 |
| [33] |
Miura Y, Matsui H . Triphenyltin impairs a protein kinase A(PKA)-dependent increase of cytosolic Na+ and Ca2+ and PKA-independent increase of cytosolic Ca2+ associated with insulin secretion in hamster pancreatic beta-cells[J]. Toxicol Appl Pharmacol, 2006,216(3):363-372
doi: 10.1016/j.taap.2006.05.017 |
| [34] |
Sievers C, Schneider HJ, Stalla GK . Insulin-like growth factor-1 in plasma and brain: regulation in health and disease[J]. Front Biosci, 2008,13:85-99
doi: 10.2741/2662 |
| [35] |
Usukura M, Zhu A, Yoneda T, Karashima S, Yagi K, Yamagishi M, Takeda Y . Effects of a high-salt diet on adipocyte glucocorticoid receptor and 11-beta hydroxysteroid dehydrogenase 1 in salt-sensitive hypertensive rats[J]. Steroids, 2009,74(12):978-982
doi: 10.1016/j.steroids.2009.07.006 |
| [36] |
Wang XL, Zhang L, Youker K, Zhang MX, Wang J , LeMaire SA, Coselli JS, Shen YH.Free fatty acids inhibit insulin signaling-stimulated endothelial nitric oxide synthase activation through upregulating PTEN or inhibiting Akt kinase[J]. Diabetes, 2006,55(8):2301-2310
doi: 10.2337/db05-1574 |
|
沪公网安备31010602003416号 沪ICP备18017633号-3
